Simak Ali

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3027317/publications.pdf

Version: 2024-02-01

25014 24232 13,274 137 57 110 citations h-index g-index papers 155 155 155 16557 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Hotspot <i>ESR1</i> Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis. Cancer Research, 2022, 82, 1321-1339.	0.4	30
2	Induction of APOBEC3-mediated genomic damage in urothelium implicates BK polyomavirus (BKPyV) as a hit-and-run driver for bladder cancer. Oncogene, 2022, 41, 2139-2151.	2.6	21
3	ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation. Nature Communications, 2022, 13, 2011.	5.8	29
4	2.5ÂÃresolution structure of human CDK-activating kinase bound to the clinical inhibitor ICEC0942. Biophysical Journal, 2021, 120, 677-686.	0.2	22
5	Detection of Multiple Breast Cancer <i>ESR1</i> Mutations on an ISFET Based Lab-on-Chip Platform. IEEE Transactions on Biomedical Circuits and Systems, 2021, 15, 380-389.	2.7	29
6	265P Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC). Annals of Oncology, 2021, 32, S477-S478.	0.6	8
7	230MO First in human, modular study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced solid malignancies. Annals of Oncology, 2021, 32, S458.	0.6	6
8	MicroRNA-495/TGF- \hat{l}^2 /FOXC1 axis regulates multidrug resistance in metaplastic breast cancer cells. Biochemical Pharmacology, 2021, 192, 114692.	2.0	12
9	Induction of APOBEC3B expression by chemotherapy drugs is mediated by DNA-PK-directed activation of NF-κB. Oncogene, 2021, 40, 1077-1090.	2.6	18
10	Circulating Tumor DNA Profiling From Breast Cancer Screening Through to Metastatic Disease. JCO Precision Oncology, 2021, 5, 1768-1776.	1.5	12
11	Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer. Cancers, 2021, 13, 6314.	1.7	3
12	ABC-transporter upregulation mediates resistance to the CDK7 inhibitors THZ1 and ICEC0942. Oncogene, 2020, 39, 651-663.	2.6	17
13	Developing themes in targeted therapies for hormone receptor–positive breast cancer. Current Opinion in Endocrine and Metabolic Research, 2020, 15, 15-23.	0.6	O
14	Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer. Breast Cancer Research, 2020, 22, 126.	2.2	14
15	Preface. Cancer and Metastasis Reviews, 2020, 39, 579-579.	2.7	O
16	CDK7 inhibitors as anticancer drugs. Cancer and Metastasis Reviews, 2020, 39, 805-823.	2.7	101
17	Endonuclease FEN1 Coregulates ERα Activity and Provides a Novel Drug Interface in Tamoxifen-Resistant Breast Cancer. Cancer Research, 2020, 80, 1914-1926.	0.4	23
18	A novel hotspot specific isothermal amplification method for detection of the common PIK3CA p.H1047R breast cancer mutation. Scientific Reports, 2020, 10, 4553.	1.6	35

#	Article	IF	Citations
19	The transcriptional repressor REV-ERB as a novel target for disease. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127395.	1.0	18
20	Beneficial effects of voluntary over forced exercise on skeletal muscle structure and myokines' expression. Folia Morphologica, 2020, 79, 350-358.	0.4	8
21	Genome-wide alterations of uracil distribution patterns in human DNA upon chemotherapeutic treatments. ELife, 2020, 9, .	2.8	13
22	90 Years of progesterone: Ninety years of progesterone: the †other†ovarian hormone. Journal of Molecular Endocrinology, 2020, 65, E1-E4.	1.1	4
23	Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer. British Journal of Cancer, 2019, 121, 776-785.	2.9	10
24	Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)—PathIES. Breast Cancer Research and Treatment, 2019, 175, 149-163.	1.1	4
25	Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence. Clinical Cancer Research, 2019, 25, 4255-4263.	3.2	281
26	Renoprotective effect of red grape (Vitis vinifera L.) juice and dark raisins against hypercholesterolemia-induced tubular renal affection in albino rats. Folia Morphologica, 2019, 78, 91-100.	0.4	3
27	Light-triggered enzymatic reactions in nested vesicle reactors. Nature Communications, 2018, 9, 1093.	5.8	125
28	ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment. Molecular Cancer Therapeutics, 2018, 17, 1156-1166.	1.9	93
29	Subdiuretic dose of furosemide enhances albuterol effects in asthmatic mice rather than bumetanide. Allergologia Et Immunopathologia, 2018, 46, 585-593.	1.0	3
30	Abstract LB-224: Circulating tumor DNA for early detection and intervention in breast cancer: ctDNA profiles discriminate between healthy women in a true cancer screening setting and disease-free women on follow up. , 2018, , .		0
31	Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts. Clinical Cancer Research, 2017, 23, 88-96.	3.2	186
32	Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ER $\hat{l}\pm$ metastatic breast cancer. Nature Genetics, 2017, 49, 444-450.	9.4	77
33	Inhibitor Selectivity for Cyclinâ€Dependent Kinaseâ€7: Aâ€Structural, Thermodynamic, and Modelling Study. ChemMedChem, 2017, 12, 372-380.	1.6	29
34	Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer. Breast Cancer Research and Treatment, 2017, 163, 461-474.	1.1	64
35	Heterodimers of photoreceptor-specific nuclear receptor (PNR/NR2E3) and peroxisome proliferator-activated receptor- $\hat{\mathbf{i}}^3$ (PPAR $\hat{\mathbf{i}}^3$) are disrupted by retinal disease-associated mutations. Cell Death and Disease, 2017, 8, e2677-e2677.	2.7	6
36	p53 controls expression of the DNA deaminase APOBEC3B to limit its potential mutagenic activity in cancer cells. Nucleic Acids Research, 2017, 45, 11056-11069.	6.5	70

#	Article	IF	CITATIONS
37	The responses of cancer cells to PLK1 inhibitors reveal a novel protective role for p53 in maintaining centrosome separation. Scientific Reports, 2017, 7, 16115.	1.6	27
38	Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance. Nature Communications, 2017, 8, 1865.	5.8	108
39	Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer. Oncogene, 2017, 36, 2286-2296.	2.6	135
40	Low Dose Iron Treatments Induce a DNA Damage Response in Human Endothelial Cells within Minutes. PLoS ONE, 2016, 11, e0147990.	1.1	39
41	LRH-1 drives colon cancer cell growth by repressing the expression of the <i>CDKN1A</i> gene in a p53-dependent manner. Nucleic Acids Research, 2016, 44, 582-594.	6.5	46
42	Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis. Breast Cancer Research and Treatment, 2016, 159, 215-227.	1.1	81
43	SAT0183â€Long-Term Efficacy, Safety, and Tolerability of Tocilizumab in Rituximab-Refractory Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 734.2-735.	0.5	1
44	Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptor–Positive Breast Cancer. Clinical Cancer Research, 2016, 22, 5929-5938.	3.2	66
45	SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer. Clinical Cancer Research, 2016, 22, 479-491.	3.2	14
46	Abstract LB-339: Mutation analysis of cell-free DNA captures heterogeneity of individual circulating tumor cells in metastatic breast cancer. , 2016, , .		0
47	Noninvasive Detection of Activating Estrogen Receptor 1 (ESR1) Mutations in Estrogen Receptor–Positive Metastatic Breast Cancer. Clinical Chemistry, 2015, 61, 974-982.	1.5	155
48	Prognostic and biological significance of peroxisome proliferator-activated receptor-gamma in luminal breast cancer. Breast Cancer Research and Treatment, 2015, 150, 511-522.	1.1	26
49	Clinical and biological significance of glucocorticoid receptor (GR) expression in breast cancer. Breast Cancer Research and Treatment, 2015, 150, 335-346.	1.1	68
50	APOBEC3B-Mediated Cytidine Deamination Is Required for Estrogen Receptor Action in Breast Cancer. Cell Reports, 2015, 13, 108-121.	2.9	105
51	Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion. Nature Communications, 2015, 6, 10044.	5.8	108
52	Expression profiling of nuclear receptors in breast cancer identifies TLX as a mediator of growth and invasion in triple-negative breast cancer. Oncotarget, 2015, 6, 21685-21703.	0.8	24
53	The Kinase LMTK3 Promotes Invasion in Breast Cancer Through GRB2-Mediated Induction of Integrin \hat{l}^2 ₁ . Science Signaling, 2014, 7, ra58.	1.6	32
54	Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer. Breast Cancer Research and Treatment, 2014, 147, 295-309.	1.1	21

#	Article	IF	CITATIONS
55	Engineered repressors are potent inhibitors of androgen receptor activity. Oncotarget, 2014, 5, 959-969.	0.8	6
56	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Research, 2013, 15, R92.	2.2	320
57	Development of a cyclin-dependent kinase inhibitor devoid of ABC transporter-dependent drug resistance. British Journal of Cancer, 2013, 109, 2356-2367.	2.9	22
58	A Common Deletion in the APOBEC3 Genes and Breast Cancer Risk. Journal of the National Cancer Institute, 2013, 105, 573-579.	3.0	141
59	Characterisation of the androgen regulation of glycine N-methyltransferase in prostate cancer cells. Journal of Molecular Endocrinology, 2013, 51, 301-312.	1.1	14
60	Co-regulated gene expression by oestrogen receptor \hat{l}_{\pm} and liver receptor homolog-1 is a feature of the oestrogen response in breast cancer cells. Nucleic Acids Research, 2013, 41, 10228-10240.	6.5	49
61	Abstract 4762: Anti-Nicastrin antibodies for the treatment of endocrine resistant breast cancer , 2013, , .		0
62	Discovery of a New Class of Liver Receptor Homologâ€1 (LRHâ€1) Antagonists: Virtual Screening, Synthesis and Biological Evaluation. ChemMedChem, 2012, 7, 1909-1914.	1.6	27
63	Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature, 2012, 481, 389-393.	13.7	1,655
64	Development of a Novel Molecular Sensor for Imaging Estrogen Receptor-Coactivator Protein-Protein Interactions. PLoS ONE, 2012, 7, e44160.	1.1	7
65	Abstract 4205: Identification of glycine N-methyltransferase-regulated genes in prostate cancer cells. , 2012, , .		0
66	Conversion of \hat{l}_{\pm} -Amino Acids into Bioactive <i>>o</i> -Aminoalkyl Resorcylates and Related Dihydroxyisoindolinones. Journal of Organic Chemistry, 2011, 76, 6209-6217.	1.7	18
67	Antiestrogens and Their Therapeutic Applications in Breast Cancer and Other Diseases. Annual Review of Medicine, 2011, 62, 217-232.	5.0	74
68	Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. Nature Medicine, 2011, 17, 715-719.	15.2	118
69	The liver receptor homolog-1 regulates estrogen receptor expression in breast cancer cells. Breast Cancer Research and Treatment, 2011, 127, 385-396.	1.1	70
70	Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growth. Breast Cancer Research and Treatment, 2011, 128, 357-368.	1.1	23
71	A simple laboratory practical to illustrate RNA mediated gene interference using drosophila cell culture. Biochemistry and Molecular Biology Education, 2010, 38, 393-399.	0.5	1
72	Concise, flexible syntheses of 4-(4-imidazolyl)pyrimidine cyclin-dependent kinase 2 (CDK2) inhibitors. Tetrahedron Letters, 2010, 51, 6126-6128.	0.7	2

#	Article	IF	CITATIONS
73	A Novel Pyrazolo[1,5- <i>a</i>]pyrimidine Is a Potent Inhibitor of Cyclin-Dependent Protein Kinases 1, 2, and 9, Which Demonstrates Antitumor Effects in Human Tumor Xenografts Following Oral Administration. Journal of Medicinal Chemistry, 2010, 53, 8508-8522.	2.9	84
74	Abstract LB-178: Characterization of estrogen responses in breast cancer cell lines highlights ERÎ \pm as an LRH-1 regulated gene. , 2010, , .		0
75	The Development of a Selective Cyclin-Dependent Kinase Inhibitor That Shows Antitumor Activity. Cancer Research, 2009, 69, 6208-6215.	0.4	135
76	The DEAD-box protein p72 regulates ERα-/oestrogen-dependent transcription and cell growth, and is associated with improved survival in ERα-positive breast cancer. Oncogene, 2009, 28, 4053-4064.	2.6	102
77	Transcriptional Coactivators and Corepressors in Endocrine Response and Resistance in Breast Cancer., 2009,, 27-38.		0
78	Microarray coupled to quantitative RT–PCR analysis of androgen-regulated genes in human LNCaP prostate cancer cells. Oncogene, 2009, 28, 2051-2063.	2.6	60
79	Regulation of ERBB2 by oestrogen receptor–PAX2 determines response to tamoxifen. Nature, 2008, 456, 663-666.	13.7	283
80	The DEAD box RNA helicases p68 (Ddx5) and p72 (Ddx17): novel transcriptional co-regulators. Biochemical Society Transactions, 2008, 36, 609-612.	1.6	93
81	ZNF366 is a novel corepressor for estrogen receptor alpha that mediates its effects through interaction with CtBP. Breast Cancer Research, 2008, 10, .	2.2	0
82	Phosphorylation at serines 104 and 106 by Erk1/2 MAPK is important for estrogen receptor- \hat{l}_{\pm} activity. Journal of Molecular Endocrinology, 2008, 40, 173-184.	1.1	108
83	Phosphorylation of Estrogen Receptor-α at Ser167 Is Indicative of Longer Disease-Free and Overall Survival in Breast Cancer Patients. Clinical Cancer Research, 2007, 13, 5769-5776.	3.2	79
84	ZNF366 is an estrogen receptor corepressor that acts through CtBP and histone deacetylases. Nucleic Acids Research, 2006, 34, 6126-6136.	6.5	55
85	Phosphorylation of ERÎ \pm at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERÎ \pm phosphorylation in breast cancer progression. Endocrine-Related Cancer, 2006, 13, 851-861.	1.6	91
86	ICI182,780 Induces p21 Gene Transcription through Releasing Histone Deacetylase 1 and Estrogen Receptor α from Sp1 Sites to Induce Cell Cycle Arrest in MCF-7 Breast Cancer Cell Line. Journal of Biological Chemistry, 2005, 280, 3185-3196.	1.6	61
87	Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation. Endocrine-Related Cancer, 2005, 12, S75-S84.	1.6	72
88	Inhibiting estrogen responses in breast cancer cells using a fusion protein encoding estrogen receptor-1± and the transcriptional repressor PLZF. Gene Therapy, 2005, 12, 452-460.	2.3	16
89	T:G mismatch-specific thymine-DNA glycosylase (TDG) as a coregulator of transcription interacts with SRC1 family members through a novel tyrosine repeat motif. Nucleic Acids Research, 2005, 33, 6393-6404.	6.5	44
90	Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. Lancet Oncology, The, 2005, 6, 383-391.	5.1	189

#	Article	IF	CITATIONS
91	Estrogen Receptors and Anti-Estrogen Therapies. , 2004, 119, 271-292.		1
92	The cooked food derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine is a potent oestrogen: a mechanistic basis for its tissue-specific carcinogenicity. Carcinogenesis, 2004, 25, 2509-2517.	1.3	80
93	Histone Deacetylase Inhibitor Trichostatin A Represses Estrogen Receptor α-Dependent Transcription and Promotes Proteasomal Degradation of Cyclin D1 in Human Breast Carcinoma Cell Lines. Clinical Cancer Research, 2004, 10, 8094-8104.	3.2	102
94	Silencing of androgen-regulated genes using a fusion of AR with the PLZF transcriptional repressor. Oncogene, 2004, 23, 7561-7570.	2.6	9
95	Tumour necrosis factor and PI3-kinase control oestrogen receptor alpha protein level and its transrepression function. British Journal of Cancer, 2004, 90, 853-859.	2.9	28
96	The Nuclear Oxysterol Receptor LXRα Is Expressed in the Normal Human Breast and in Breast Cancer. Medical Oncology, 2004, 21, 123-132.	1.2	26
97	Mechanisms of Tamoxifen Resistance: Increased Estrogen Receptor-HER2/neu Cross-Talk in ER/HER2-Positive Breast Cancer. Journal of the National Cancer Institute, 2004, 96, 926-935.	3.0	1,048
98	Reporter gene assay demonstrates functional differences in estrogen receptor activity in purified breast cancer cells: A pilot study. International Journal of Cancer, 2003, 107, 700-706.	2.3	7
99	T:G Mismatch-specific Thymine-DNA Glycosylase Potentiates Transcription of Estrogen-regulated Genes through Direct Interaction with Estrogen Receptor $\hat{l}\pm$. Journal of Biological Chemistry, 2003, 278, 38586-38592.	1.6	108
100	Enhanced Estrogen Receptor (ER) \hat{l}_{\pm} , ERBB2, and MAPK Signal Transduction Pathways Operate during the Adaptation of MCF-7 Cells to Long Term Estrogen Deprivation. Journal of Biological Chemistry, 2003, 278, 30458-30468.	1.6	269
101	Purified malignant mammary epithelial cells maintain hormone responsiveness in culture. British Journal of Cancer, 2003, 88, 1071-1076.	2.9	15
102	Gene ICE as Applied to Studies of Hormonally-Responsive Cancers. Clinical Science, 2003, 104, 27P-27P.	0.0	0
103	Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. Journal of Steroid Biochemistry and Molecular Biology, 2002, 81, 333-341.	1.2	130
104	Phosphorylation of human estrogen receptor \hat{l}_{\pm} at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene, 2002, 21, 4921-4931.	2.6	227
105	Endocrine-responsive breast cancer and strategies for combating resistance. Nature Reviews Cancer, 2002, 2, 101-112.	12.8	759
106	Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor \hat{l}_{\pm} . Journal of Biological Chemistry, 2001, 276, 9817-9824.	1.6	831
107	Analysis of estrogenâ€responsive finger protein expression in benign and malignant human breast. International Journal of Cancer, 2001, 91, 152-158.	2.3	14
108	Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clinical Cancer Research, 2001, 7, 971-6.	3.2	315

#	Article	IF	Citations
109	Estrogen receptor alpha in human breast cancer: occurrence and significance. , 2000, 5, 271-281.		264
110	Activation of Estrogen Receptor \hat{l}_{\pm} by S118 Phosphorylation Involves a Ligand-Dependent Interaction with TFIIH and Participation of CDK7. Molecular Cell, 2000, 6, 127-137.	4.5	270
111	Activation of estrogen receptor alpha by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7. Molecular Cell, 2000, 6, 127-37.	4.5	113
112	Phosphorylation of Human Estrogen Receptor \hat{l}_\pm by Protein Kinase A Regulates Dimerization. Molecular and Cellular Biology, 1999, 19, 1002-1015.	1.1	224
113	An important role for BRCA1 in breast cancer progression is indicated by its loss in a large proportion of non-familial breast cancers., 1998, 79, 334-342.		105
114	Localization and expression of the human estrogen receptor beta gene in uterine leiomyomata., 1998, 23, 361-366.		45
115	Effect of Norplant on liver function. Bangladesh Medical Research Council Bulletin, 1998, 24, 10-3.	0.1	0
116	Human Estrogen Receptor \hat{l}^2 Binds DNA in a Manner Similar to and Dimerizes with Estrogen Receptor \hat{l}_\pm . Journal of Biological Chemistry, 1997, 272, 25832-25838.	1.6	264
117	Presence of exon 5-deleted oestrogen receptor in human breast cancer: functional analysis and clinical significance. British Journal of Cancer, 1997, 75, 1173-1184.	2.9	40
118	Response of a new ceramic-oxynitride (Cernox) resistance temperature sensor in high magnetic fields. Cryogenics, 1996, 36, 61-63.	0.9	12
119	Simultaneous measurement of cyclopentyladenosine-induced contraction and intracellular calcium in bronchial rings from allergic rabbits and it's antagonism. Journal of Pharmacology and Experimental Therapeutics, 1996, 278, 639-44.	1.3	9
120	Effect of antagonists on DNA binding properties of the human estrogen receptor in vitro and in vivo Molecular Endocrinology, 1995, 9, 579-591.	3.7	100
121	Characterization of the Amino-terminal Transcriptional Activation Function of the Human Estrogen Receptor in Animal and Yeast Cells. Journal of Biological Chemistry, 1995, 270, 9535-9542.	1.6	207
122	Adenosine receptor-mediated bronchoconstriction and bronchial hyperresponsiveness in allergic rabbit model. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1994, 266, L271-L277.	1.3	24
123	Competitive interactions in catalytic hydroprocessing of middle distillates. International Journal of Energy Research, 1994, 18, 177-183.	2.2	0
124	Adenosine-induced bronchoconstriction and contraction of airway smooth muscle from allergic rabbits with late-phase airway obstruction: evidence for an inducible adenosine A1 receptor. Journal of Pharmacology and Experimental Therapeutics, 1994, 268, 1328-34.	1.3	65
125	Different TBP-associated factors are required for mediating the stimulation of transcriptionin vitroby the acidic transactivator GAL-VP16 and the two nonacidic activation functions of the estrogen receptor. Nucleic Acids Research, 1993, 21, 5-12.	6.5	88
126	Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region EMBO Journal, 1993, 12, 1153-1160.	3.5	388

#	Article	IF	CITATIONS
127	Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region. EMBO Journal, 1993, 12, 1153-60.	3.5	130
128	Retinoic acid receptor-beta: immunodetection and phosphorylation on tyrosine residues Molecular Endocrinology, 1992, 6, 2197-2209.	3.7	68
129	Immunodetection of multiple species of retinoic acid receptor α: Evidence for phosphorylation. Experimental Cell Research, 1992, 201, 335-346.	1.2	127
130	Adenosine-induced bronchoconstriction in an allergic rabbit model: Antagonism by theophylline aerosol. Agents and Actions, 1992, 37, 165-167.	0.7	21
131	Modification of allergen-induced airway obstruction and bronchial hyperresponsiveness in the allergic rabbit by theophylline aerosol. Agents and Actions, 1992, 37, 168-170.	0.7	18
132	Diminution in phase I and phase II drug metabolizing enzymes of rat lung by asbestos: Anin vitro study. Bulletin of Environmental Contamination and Toxicology, 1991, 47, 660-667.	1.3	0
133	Developmental regulation of the sheep \hat{l}^2 -lactoglobulin gene in the mammary gland of transgenic mice. Genesis, 1991, 12, 299-307.	3.3	52
134	Preparation and characterization of Bi-based high Tc superconductors. Materials Research Bulletin, 1990, 25, 779-784.	2.7	7
135	Characterisation of the alleles encoding ovine ß-lactoglobulins A and B. Gene, 1990, 91, 201-207.	1.0	20
136	Characterization of the gene encoding ovine beta-lactoglobulin. Journal of Molecular Biology, 1988, 199, 415-426.	2.0	121
137	Complete nucleotide sequence of the genomic ovine \hat{l}^2 -lactoglobulin gene. Nucleic Acids Research, 1988, 16, 10379-10380.	6.5	53